- Home
- BLFS vs ZYME Comparison
BLFS vs ZYME Comparison
Compare BLFS & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLFS
- ZYME
- Stock Information
- Founded
- BLFS 1987
- ZYME 2003
- Country
- BLFS United States
- ZYME United States
- Employees
- BLFS N/A
- ZYME N/A
- Industry
- BLFS Medical/Dental Instruments
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- BLFS Health Care
- ZYME Health Care
- Exchange
- BLFS Nasdaq
- ZYME Nasdaq
- Market Cap
- BLFS 1.2B
- ZYME 983.6M
- IPO Year
- BLFS 1989
- ZYME 2017
- Fundamental
- Price
- BLFS $26.67
- ZYME $14.39
- Analyst Decision
- BLFS Strong Buy
- ZYME Buy
- Analyst Count
- BLFS 7
- ZYME 6
- Target Price
- BLFS $29.43
- ZYME $19.17
- AVG Volume (30 Days)
- BLFS 251.1K
- ZYME 340.7K
- Earning Date
- BLFS 03-03-2025
- ZYME 03-05-2025
- Dividend Yield
- BLFS N/A
- ZYME N/A
- EPS Growth
- BLFS N/A
- ZYME N/A
- EPS
- BLFS N/A
- ZYME N/A
- Revenue
- BLFS $146,957,000.00
- ZYME $62,199,000.00
- Revenue This Year
- BLFS N/A
- ZYME $21.53
- Revenue Next Year
- BLFS N/A
- ZYME N/A
- P/E Ratio
- BLFS N/A
- ZYME N/A
- Revenue Growth
- BLFS 16.40
- ZYME N/A
- 52 Week Low
- BLFS $14.50
- ZYME $7.97
- 52 Week High
- BLFS $29.55
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- BLFS 47.11
- ZYME 49.88
- Support Level
- BLFS $25.84
- ZYME $14.45
- Resistance Level
- BLFS $28.92
- ZYME $15.25
- Average True Range (ATR)
- BLFS 1.20
- ZYME 0.73
- MACD
- BLFS 0.02
- ZYME -0.02
- Stochastic Oscillator
- BLFS 38.69
- ZYME 64.58
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing, and marketing a portfolio of biopreservation tools and services for cells, tissues, and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.